GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (BUE:LLY) Cyclically Adjusted PS Ratio : 19.18 (As of May. 22, 2025)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2025-05-22), Eli Lilly and Co's current share price is ARS15075.00. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ARS786.11. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 19.18.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:LLY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.23   Med: 6.5   Max: 31.37
Current: 21.63

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 31.37. The lowest was 3.23. And the median was 6.50.

BUE:LLY's Cyclically Adjusted PS Ratio is ranked worse than
98.1% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BUE:LLY: 21.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Mar. 2025 was ARS60,266.449. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS786.11 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.43 11.14 13.57 20.20 23.93

Eli Lilly and Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.12 29.59 28.24 23.93 24.64

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


;
;

Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=15075.00/786.11
=19.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=60266.449/134.9266*134.9266
=60,266.449

Current CPI (Mar. 2025) = 134.9266.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 169.816 100.684 227.571
201509 175.113 100.392 235.353
201512 261.349 99.792 353.363
201603 267.331 100.470 359.012
201606 285.096 101.688 378.285
201609 292.018 101.861 386.811
201612 343.302 101.863 454.735
201703 305.234 102.862 400.382
201706 363.376 103.349 474.403
201709 375.560 104.136 486.606
201712 238.809 104.011 309.791
201803 381.084 105.290 488.352
201806 540.827 106.317 686.363
201809 761.137 106.507 964.236
201812 832.556 105.998 1,059.775
201903 809.163 107.251 1,017.968
201906 1,089.518 108.070 1,360.282
201909 1,333.846 108.329 1,661.334
201912 1,596.686 108.420 1,987.043
202003 1,595.760 108.902 1,977.112
202006 1,653.261 108.767 2,050.882
202009 1,870.450 109.815 2,298.171
202012 2,648.820 109.897 3,252.108
202103 2,687.630 111.754 3,244.908
202106 2,805.315 114.631 3,301.989
202109 2,908.407 115.734 3,390.710
202112 3,490.826 117.630 4,004.143
202203 3,700.687 121.301 4,116.381
202206 3,458.638 125.017 3,732.796
202209 4,268.800 125.227 4,599.463
202212 5,410.737 125.222 5,830.074
202303 6,088.555 127.348 6,450.901
202306 8,839.721 128.729 9,265.327
202309 14,776.773 129.860 15,353.361
202312 14,943.319 129.419 15,579.204
202403 32,693.251 131.776 33,474.855
202406 44,776.188 132.554 45,577.711
202409 48,056.858 133.029 48,742.405
202412 60,543.004 133.157 61,347.549
202503 60,266.449 134.927 60,266.449

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.